Skip to main content
NBP logo

NBP

NovaBridge Biosciences
$2.02 +0.01 (+0.50%) At close · Jul 7
Market Cap
$536.06M
Shares
265,377,891

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.02 Open$2.01 Day$1.95–2.05 52W$1.46–6.79 Avg vol 30d686K Short int4.2M · 1.6% float · 8.5d Short vol49% DataJan 2020–Jul 2026
Equibles Rating blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 16.9 · calm Equity put/call 0.86
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −38%
below
Price vs 50-day avg +7%
above
RSI (14) 61
neutral
MACD trend Positive
52-week position 11%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +23%
trailing
6-month return −46%
trailing
YTD return −49%
this year
Relative strength −53%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Distributing
-16% holders QoQ · +8 funds added
Insider flow Accumulating
Net +$511.4K over 90 days · 75% sells
Short interest Rising
1.57% of float · ▲ +16.1% MoM · 8.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
49 holders — mid 3-yr range
Squeeze score 50
elevated · 0–100
Fundamentals
Strong
Revenue growth +141%
Y/Y
EPS growth −75%
Y/Y
Free cash flow $-183.8M
Buyback $40.0M
authorized
Balance sheet $210.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 97%
annualized · 1-yr
Max drawdown −78%
past year
ATR 7.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next
FQ3-26 quarter ends
~Sep 30, 2026 Est

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−38% Bearish
Price vs 50-day avg
+7% Bullish
RSI (14)
61 Neutral
MACD trend
Positive Bullish
52-week position
11% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Distributing
-16% holders QoQ · +8 funds added
Insider flow Accumulating
Net +$511.4K over 90 days · 75% sells
Short interest Rising
1.57% of float · ▲ +16.1% MoM · 8.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
49 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1 Now $2 · 11% 52-wk high $7
vs 200-day avg -38% vs 50-day avg +7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NBP
NovaBridge Biosciences
this stock
$536.06M -49.2% +140.7% 1.6%
ONC
BeOne Medicines Ltd.
$446.53B +1.7% +22179.2% 908.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$126.50B +9.9% +46.2% 29.6 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
$69.50B -14.0% +20.8% 16.2 3.2%
ARGX
Argenx SE
$57.20B +8.8% 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
49
% held
11.1%
Net QoQ
-3.9M sh
Top holder
JANUS HENDERSON GROUP PLC
Held Float
View
Held by Funds
Fund positions
15
View
Short & Settlement
Short Interest Rising
Shares short
4.2M
Days to cover
8.5d
Change
+576.8K sh
View
Short Volume
Short vol %
49%
As of
Jul 8, 2026
Short Total
View
Fails to Deliver
FTD shares
2.0K
Value
$3.0K
As of
Jun 11, 2026
View
Off-Exchange
Off-exchange %
39.2%
Week of
May 4, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$511.4K
Buyers / Sellers
1 / 3
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$632.0K
Net income (FY)
$-46.3M
EPS diluted
$-0.21
View
Buybacks
Authorized
$40.0M
View
Filings
SEC Filings
Latest
6-K
Filed
Jun 29, 2026
This year
17
View
Proposed Sales
Value
$18.5K
Shares
9.3K
Filed
May 14, 2026
View

Performance

5D 20D 120D MTD YTD
NBP +2.0% +22.8% -45.7% +3.6% -49.3%
SPY +0.9% +1.4% +7.6% +0.1% +9.7%
vs SPY +1.1% +21.4% -53.3% +3.5% -58.9%

Capital returns

Buyback program · as of Dec 31, 2025
Authorized
$40.00M
Spent (derived)
Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1778016 CUSIP 44975P103 13F (30d) 7 filings 1 filers Visit website